Eligible patients with paroxysmal or persistent NVAF , a left ventricular ejection fraction > @ % , and a creatinine clearance > @mL/min will be randomized @:@ to rivaroxaban @mg orally once daily or to dose-adjusted oral VKA ( recommended international normalized ratio ( INR ) @-@ @ ) and stabilized on anticoagulation therapy for @-@days ( if no intracardiac thrombus on transesophageal echocardiogram ( TEE ) immediately prerandomization/post-randomization or if @weeks of sufficient anticoagulation is documented ) or for @-@weeks ( if no TEE , no documented @weeks of sufficient anticoagulation , or by patient choice ) .